Sign In
Buy CTXR
$0.570
-0.0620 (-9.81%)
At Close: Jul 31, 2026
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today the publi
Citius Pharmaceuticals to Deliver Virtual Presentation at the Spring Investor Summit
01:46pm, Wednesday, 18'th Mar 2020
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that Chie
Here's Why We Worry About Citius Pharmaceuticals's (NASDAQ:CTXR) Cash Burn Situation
10:22am, Monday, 16'th Mar 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Citius Pharmaceuticals, Inc. to Present at the Spring Investor Summit on March 25th-26th in New York City
09:45pm, Tuesday, 03'rd Mar 2020
NEW YORK, NY / ACCESSWIRE / March 3, 2020 / Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), is a specialty pharmaceutical company dedicated to the development and commercialization of drug products that a
Alternative real estate assets: get ready for the floats
01:25pm, Wednesday, 26'th Feb 2020
The local stock exchange is beckoning ever more strongly for a growing range of REITs focused on alternative asset classes.
Citius Pharmaceuticals to Present at the 2020 LD Micro Virtual Conference
01:00pm, Wednesday, 26'th Feb 2020
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the
Citius Pharmaceuticals Cites Independent Estimates of Total Available World Market for Mino-Lok®
01:00pm, Tuesday, 25'th Feb 2020
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today cited independent r
Citius Pharmaceuticals to Present at Noble Capital Markets' 16th Annual Investor Conference
01:28pm, Monday, 10'th Feb 2020
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today that the
ASX snaps three-day losing streak: Aus shares 0.1% higher at noon
05:25am, Monday, 10'th Feb 2020
24 Oct 2018 - Market at Midday. ASX claws back from earlier fall. Citi issues alert for Healthscope (ASX:HSO) saying new takeover offer is a 32% premium. Brambles (ASX:BXB) and Centuria Metro. REIT (A
Citius Achieves 50% Patient Enrollment in Phase 3 Mino-Lok® Pivotal Trial
01:00pm, Tuesday, 04'th Feb 2020
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical-care drug products, today announced that the
Citi Bank Backs Cobalt’s Forex Post-Trade Infrastructure | Finance Magnates
09:00am, Tuesday, 04'th Feb 2020
Cobalt, the FX post-trade infrastructure, has announced this Tuesday that Citi bank is the latest market player to support its infrastructure.
Citius Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
01:00pm, Monday, 03'rd Feb 2020
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that it receive
Biotech Companies Think Big with Specialization - Fighting Deadly Bacteria and Viruses
01:00pm, Monday, 27'th Jan 2020
Point Roberts, Washington and Vancouver, British Columbia--(Newsfile Corp. - January 27, 2020) - Investorideas.com, a leading investor news resource covering pharmaceutical and biotechnology stocks re
YieldStreet Announces New Partnership With Citi For Access to Private Credit Opportunities Delivery
04:23pm, Wednesday, 08'th Jan 2020
Click HERE to find out ⭐ YieldStreet Announces New Partnership With Citi For Access to Private Credit Opportunities Delivery. | Crowdfund Insider: Global Fintech News, including Crowdfunding, Blockc
Citius Announces Positive Outcome of Interim Futility Analysis for its Phase 3 Mino-Lok® Pivotal Trial
01:00pm, Thursday, 19'th Dec 2019
Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (NASDAQ: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced a positiv
